Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 5/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446091 | 1.00 | CHRNB4 (0.48) | CHRNB4CHRNA3ALOX5APFEN1FAAH | |
| SCHEMBL1264856 | 1.00 | CHRNB4 (0.48) | CHRNB4CHRNA3ALOX5APFEN1FAAH | |
| SCHEMBL6215959 | 0.92 | CHRNB4 (0.42) | CHRNB4CHRNA3ALOX5APFEN1GPR119 | |
| SCHEMBL4098323 | 0.88 | CHRNB4 (0.52) | CHRNB4CHRNA3FAAH | |
| SCHEMBL6225147 | 0.88 | CHRNB4 (0.52) | CHRNB4CHRNA3FAAH | |
| SCHEMBL25594927 | 0.87 | CHRNB4 (0.51) | CHRNB4CHRNA3ALOX5APFEN1FAAH | |
| SCHEMBL25594933 | 0.87 | CHRNB4 (0.51) | CHRNB4CHRNA3ALOX5APFEN1FAAH | |
| SCHEMBL447803 | 0.84 | ALOX5AP (0.47) | CHRNB4CHRNA3ALOX5APFEN1GPR119 | |
| SCHEMBL444388 | 0.84 | ALOX5AP (0.47) | CHRNB4CHRNA3ALOX5APFEN1GPR119 | |
| SCHEMBL444389 | 0.84 | ALOX5AP (0.47) | CHRNB4CHRNA3ALOX5APFEN1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| CN-1538836-A | Substituted amine derivatives and method of use | ��������ķ������ | 2004-10-20 | — | — | CN | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | CHRNB4 3031/4885CHRNA3 2615/4885ALOX5AP 109/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CHRNB4 4141/4885CHRNA3 4231/4885ALOX5AP 562/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | CHRNB4 3504/4885CHRNA3 2996/4885ALOX5AP 94/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CHRNB4 3455/4885CHRNA3 2850/4885ALOX5AP 117/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CHRNB4 4141/4885CHRNA3 4231/4885ALOX5AP 562/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | CHRNB4 3520/4885CHRNA3 3218/4885ALOX5AP 607/4885 |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | CHRNB4 4878/4885CHRNA3 4833/4885ALOX5AP 85/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CHRNB4 4141/4885CHRNA3 4231/4885ALOX5AP 562/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | CHRNB4 3520/4885CHRNA3 3218/4885ALOX5AP 607/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CHRNB4 3455/4885CHRNA3 2850/4885ALOX5AP 117/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | CHRNB4 3877/4885CHRNA3 3546/4885ALOX5AP 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.